Abstract
Drug resistance is a common concern for the development of novel antiviral, antimicrobial and anticancer therapies. To overcome this problem, several strategies have been developed, many of which involving the theme of this review, the use of structure-based drug design (SBDD) approaches. These include the successful design of new compounds that target resistant mutant proteins, as well as the development of drugs that target multiple proteins involved in specific biochemical pathways. Finally, drug resistance can also be considered in the early stages of drug discovery, through the use of strategies to delay the development of resistance. The purpose of this brief review is to underline the usefulness of SBDD approaches based on case studies, highlighting present challenges and opportunities in drug design.
Keywords: Drug discovery, drug resistance, structure-based drug design, therapeutic agents.
Current Pharmaceutical Design
Title:Structure-Based Drug Design to Overcome Drug Resistance: Challenges and Opportunities
Volume: 20 Issue: 5
Author(s): Rafaela S. Ferreira and Adriano D. Andricopulo
Affiliation:
Keywords: Drug discovery, drug resistance, structure-based drug design, therapeutic agents.
Abstract: Drug resistance is a common concern for the development of novel antiviral, antimicrobial and anticancer therapies. To overcome this problem, several strategies have been developed, many of which involving the theme of this review, the use of structure-based drug design (SBDD) approaches. These include the successful design of new compounds that target resistant mutant proteins, as well as the development of drugs that target multiple proteins involved in specific biochemical pathways. Finally, drug resistance can also be considered in the early stages of drug discovery, through the use of strategies to delay the development of resistance. The purpose of this brief review is to underline the usefulness of SBDD approaches based on case studies, highlighting present challenges and opportunities in drug design.
Export Options
About this article
Cite this article as:
Ferreira S. Rafaela and Andricopulo D. Adriano, Structure-Based Drug Design to Overcome Drug Resistance: Challenges and Opportunities, Current Pharmaceutical Design 2014; 20 (5) . https://dx.doi.org/10.2174/138161282005140214161949
DOI https://dx.doi.org/10.2174/138161282005140214161949 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
HIF-1α Deficiency Perturbs T and B Cell Functions
Current Pharmaceutical Design Coordinated Expression of Pax-5 and FAK1 in Metastasis
Anti-Cancer Agents in Medicinal Chemistry Modulating Mitochondria-Mediated Apoptotic Cell Death through Targeting of Bcl-2 Family Proteins
Recent Patents on DNA & Gene Sequences Anti-Apoptotic Mechanisms of Drug Resistance in Cancer
Current Cancer Drug Targets Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry Transcription Factors as Potential Targets for Therapeutic Drugs
Current Pharmaceutical Biotechnology Importance of Wnt Signaling in the Tumor Stroma Microenvironment
Current Cancer Drug Targets New Technologies: Non-Hormonal Female Contraception
Current Women`s Health Reviews Fragment-Based Discovery of Inhibitors of Protein Kinase B
Current Topics in Medicinal Chemistry Retinoids as Critical Modulators of Immune Functions: New Therapeutic Perspectives for Old Compounds
Endocrine, Metabolic & Immune Disorders - Drug Targets Cytisine - From the Past to the Future
Current Pharmaceutical Design Non-Genotoxic p53-Activators and their Significance as Antitumor Therapy of Future
Current Medicinal Chemistry Perspectives for Novel Mixed Diruthenium-Organic Drugs as Metallopharmaceuticals in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Paraneoplastic Pemphigus: Autoimmune-Cancer Nexus in the Skin
Anti-Cancer Agents in Medicinal Chemistry Emerging Roles for Modulation of microRNA Signatures in Cancer Chemoprevention
Current Cancer Drug Targets Nutlins and Ionizing Radiation in Cancer Therapy
Current Pharmaceutical Design Therapeutic Strategies for Targeting BRAF in Human Cancer
Reviews on Recent Clinical Trials MicroRNAs - Key Players in Haematopoiesis
Current Signal Transduction Therapy Culture Supernatants from Lactobacillus plantarum Induce Necrosis on a Human Promyelocytic Leukemia Cell Line
Endocrine, Metabolic & Immune Disorders - Drug Targets DNA Copy Number Profiles Correlate with Outcome in Colorectal Cancer Patients Treated with Fluoropyrimidine/Antifolate-based Regimens
Current Drug Metabolism